The galectin-3 inhibitor belapectin is the first potential therapy to show clinically significant effect in patients with NASH cirrhosis before the development of esophageal varices.
The only Phase 2b/3 clinical trial focused on the symptoms of NASH cirrhosis instead of liver biopsies
There are currently no approved therapies for NASH cirrhosis, short of a liver transplant.
The prevention of varices eliminates the risk of bleeding varices
Bleeding varices threaten the life of cirrhotic patients.
Approximately 50% of cirrhotic NASH patients with portal hypertension do not have varices when first evaluated
The development of varices is seen as the first sign of serious cirrhosis complications.
What is NASH Cirrhosis?
NASH cirrhosis is the end stage of non-alcoholic steatohepatitis (NASH), where scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH have replaced healthy liver tissue, preventing the liver from functioning normally.
NASH cirrhosis will soon become the number one reason for liver transplants.
Galectin Therapeutics Inc. has developed several overarching principles to guide its conduct of clinical research in light of COVID-19. Number one among these is the safety of patients and study site personnel. Health authorities have provided guidance for the conduct of clinical studies during this pandemic, and we follow this guidance carefully. Participants are encouraged to contact their study site directly with any questions or concerns.